Diagnostic Performance of a Commercial Assay for the Detection of Neuronal Antibodies

CompletedOBSERVATIONAL
Enrollment

34

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

July 15, 2021

Study Completion Date

February 28, 2022

Conditions
Paraneoplastic Neurological SyndromeAutoimmune Encephalitis
Interventions
DIAGNOSTIC_TEST

Indirect immunofluorescence assay on tissue slides and cell-based assays with CSF and/or sera

Sera and/or CSF samples are drawn from patients with a clinical suspicion of autoimmune encephalitis or paraneoplastic neurological syndrome. Indirect immunofluorescence assays will be performed on commercial and in-house slides upon receipt in our center. In case of positive staining, additional tests such as cell-based assays, western-blots, ELISA or immunodots can be performed.

Trial Locations (2)

69500,

Hospice Civils de Lyon, Bron

Unknown

Hospices Civils de Lyon, Pierre-Bénite

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT05783947 - Diagnostic Performance of a Commercial Assay for the Detection of Neuronal Antibodies | Biotech Hunter | Biotech Hunter